About Medtronic (NYSE:MDT)

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Friday, December 8th. Investors of record on Friday, December 29th will be paid a dividend of $0.46 per share on Friday, January 19th. This represents a $1.84 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date is Thursday, December 28th. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic declared that its board has approved a stock repurchase program on Thursday, October 5th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 49% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's leadership believes its stock is undervalued.

How were Medtronic's earnings last quarter?

Medtronic plc. (NYSE:MDT) posted its quarterly earnings results on Tuesday, February, 20th. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.16 by $0.01. The medical technology company had revenue of $7.37 billion for the quarter, compared to analyst estimates of $7.20 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The firm's revenue was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.12 EPS. View Medtronic's Earnings History.

When will Medtronic make its next earnings announcement?

Where is Medtronic's stock going? Where will Medtronic's stock price be in 2018?

22 brokerages have issued twelve-month price targets for Medtronic's stock. Their predictions range from $80.00 to $99.00. On average, they expect Medtronic's share price to reach $90.86 in the next twelve months. View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:

1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)

2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)

3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)

4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)

Who sold Medtronic stock? Who is selling Medtronic stock?

Medtronic's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Barrow Hanley Mewhinney & Strauss LLC, PGGM Investments, Credit Agricole S A and King Luther Capital Management Corp. Company insiders that have sold Medtronic company stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Who bought Medtronic stock? Who is buying Medtronic stock?

Medtronic's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., HealthCor Management L.P., Rockefeller Financial Services Inc., Boston Partners, Vontobel Asset Management Inc., Mackenzie Financial Corp, The Manufacturers Life Insurance Company and Sterling Capital Management LLC. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.

How do I buy Medtronic stock?

Shares of Medtronic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of Medtronic stock can currently be purchased for approximately $80.72.

How big of a company is Medtronic?

Medtronic has a market capitalization of $110.46 billion and generates $29.71 billion in revenue each year. The medical technology company earns $4.03 billion in net income (profit) each year or $3.64 on an earnings per share basis. Medtronic employs 91,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]

MarketBeat Community Rating for Medtronic (MDT)

MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Medtronic (NYSE:MDT) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.